

The GABA_{B2} subunit is critical for the trafficking and function of native GABA_B receptors

Seb J. Thuaud^{a,e,1}, Jon T. Brown^{a,e,1}, Steven A. Sheardown^{c,1}, Sabine Jourdain^a, Benjamin Fairfax^d, Jonathan P. Spencer^a, Sophie Restituito^d, Josephine H.L. Nation^c, Stephanie Topps^c, Andrew D. Medhurst^a, Andrew D. Randall^a, Andres Couve^d, Stephen J. Moss^d, Graham L. Collingridge^e, Menelas N. Pangalos^{a,2}, Ceri H. Davies^b, Andrew R. Calver^{a,*}

^aNeurology and GI CEDD, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK

^bPsychiatry CEDD, GlaxoSmithKline, Third Avenue, Harlow, Essex CM19 5AW, UK

^cComparative Genomics, GlaxoSmithKline, Third Avenue, Harlow, Essex CM19 5AW, UK

^dMedical Research Council Laboratory for Molecular Cell Biology, Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK

^eMRC Centre for Synaptic Plasticity, Department of Anatomy, University of Bristol, University Walk, Bristol BS8 1TD, UK

Received 1 July 2004; accepted 12 July 2004

Abstract

Studies in heterologous systems have demonstrated that heterodimerisation of the two GABA_B receptor subunits appears to be crucial for the trafficking and signalling of the receptor. Gene targeting of the GABA_{B1} gene has demonstrated that the expression of GABA_{B1} is essential for GABA_B receptor function in the central nervous system (CNS). However, the contribution of the GABA_{B2} subunit in the formation of native GABA_B receptors is still unclear, in particular whether other proteins can substitute for this subunit. We have created a transgenic mouse in which the endogenous GABA_{B2} gene has been mutated in order to express a C-terminally truncated version of the protein. As a result, the GABA_{B1} subunit does not reach the cell surface and concomitantly both pre- and post-synaptic GABA_B receptor functions are abolished. Taken together with previous gene deletion studies for the GABA_{B1} subunit, this suggests that classical GABA_B function in the brain is exclusively mediated by GABA_{B1/2} heteromers.

© 2004 Elsevier Inc. All rights reserved.

Keywords: GABA_B receptors; GPCR; Transgenic; Trafficking; Synaptic physiology; Epilepsy

1. Introduction

GABA receptors are the major inhibitory receptors in the central nervous system (CNS). Whilst GABA_A and GABA_C receptors are ionotropic and mediate fast synaptic inhibition, GABA_B receptors are metabotropic G protein coupled receptors (GPCR) that induce slower and more prolonged effects via the activation of an array of downstream effector systems, such as inhibition of adenylyl-

cyclase, inhibition of presynaptic calcium channels and activation of postsynaptic potassium channels. Their far-reaching effects together with their widespread distribution have raised expectations that this receptor class will be of clinical importance for pharmaceutical intervention in a number of disease areas, including asthma, epilepsy, depression, anxiety, drug addiction, anti-nociception, anti-spasticity and cognitive enhancement for patients affected with neurodegenerative conditions such as Alzheimer's disease (for review see [1]).

Molecular biological and biochemical approaches have demonstrated that, in contrast to the established dogma for the G protein coupled receptor superfamily, the GABA_B receptor exists as a heterodimer rather than as a single subunit [1–6]. Whilst its homology to metabotropic glu-

* Corresponding author. Tel.: +44 1279 622690; fax: +44 1279 622470.
E-mail address: andrew.r.calver@gsk.com (A.R. Calver).

¹ These authors contributed equally to this work.

² Present address: Wyeth Research, Neuroscience Discovery, 865 Ridge Road, Princeton, NJ 08852, USA.

tamate receptors suggests that multiple GABA_B receptor subunits may be encoded within the mammalian genome, to date only two distinct genes have been cloned [3,4,7]. Extensive investigation of the functionality of these subunits has led to the concept that the GABA_B receptor consists of a GABA_{B1} subunit that binds the endogenous ligand within its extracellular N-terminus, and a GABA_{B2} subunit that fulfils at least two roles: (1) it is essential for the correct trafficking of the GABA_{B1} receptor subunit to the cell surface to form a functional dimeric receptor and (2) it is responsible for the interaction of the receptor with its cognate G protein. In this respect, we and others have identified key structural determinants within both GABA_{B1} and GABA_{B2} that are important in carrying out these functions in vitro [8–11]. In particular, the coupling of the receptor to its G protein is mediated not by the intracellular C-terminus of either subunit, but instead by specific positively-charged residues located within the second intracellular domain of the GABA_{B2} receptor subunit [12–15]. Indeed, deletion of the C-termini of both GABA_{B1} and GABA_{B2} result in a functional GABA_B receptor in transfected cells. However, transfection of a C-terminally deleted form of GABA_{B2} in conjunction with a full-length GABA_{B1} subunit does not result in a functional GABA_B receptor [9]. This is because, at least in transfected cells, the C-terminal of GABA_{B2} is necessary to mask the ER-retention signal present in the C-terminal of GABA_{B1} and result in the correct trafficking of GABA_{B1} to the cell surface, a prerequisite for the assembly of a functional GABA_B receptor.

In the present study, we have generated a mouse in which the intracellular C-terminus of GABA_{B2} has been deleted (termed Δ GB2-Ct), and tested the influence of this truncated version of the protein on the function and trafficking of native GABA_B receptors. Although it is not possible to directly demonstrate the Δ GB2-Ct protein in these mice, we provide overwhelming indirect evidence for its stable expression, and thus demonstrate that classical GABA_B responses in the CNS are dependent on the correct trafficking of the GABA_{B1} subunit to the plasma membrane by full-length GABA_{B2}, and that no other protein can perform this function in the absence of a functional GABA_{B2} subunit.

2. Materials and methods

2.1. Targeting of GABA_{B2} gene and generation of mutant mice

Gene targeting was performed in E14.1 embryonic stem (ES) cells, replacing exons 14 and 15 of the mouse GABA_{B2} locus with a positive selection cassette containing the pgk promoter/neomycin phosphotransferase gene. Homology arms were generated by PCR using primers BR2.10F–BR2.9R and BR2.15F–BR2.14R (see Table 1)

Table 1

Primers for generating homology arms by PCR

BR2.10F	CAGCCCAACGTGCAGTTCTGCATCGTGGCC
BR2.9R	TGGTGACTGAGGTGGAGGTCTTCGAATCTT
BR2.15F	TCAACGACATCCTCAGCTTGGGCAAC
BR2.14R	GGAGCTGAGGGTTTGTATCGAGGTGA
BR2.9F	GTGTACAATGTGGGGATCATGTGCATCATC
BR2.8F	TGGGAAACCCGCAACGTGAGCATCCCT
NeoR3.1	TGCCAGTCATAGCCGAATAGCC

spanning coding exons 13–14 and 15–16, respectively. The entire 3.6 kb BR2.10F–9R product was used as 5' homology arm, the 3' homology arm was subcloned from the 7 kb BR2.15F–14R PCR product by XbaI digest which removed 3 kb from the 3' end of the product. The arms were cloned either side of a PGK-neo cassette positioned to replace exons 14 and 15, causing termination of translation at the exon 14/PGK-neo interface. The 3' homology arm was flanked by the Diphtheria-toxin A gene as a negative selection marker (DTA). In order to screen for ES cells carrying the mutation, an 800 bp external probe was excised from the BR2.15F–14R PCR product by digestion with BstX1 and XbaI, and this was used to probe BstX1-digested genomic DNA. The wild type allele generates a 5.2 kb band while the KO allele gives rise to a band of 5.5 kb (Fig. 1A). One thousand and two hundred G418 resistant clones were screened by Southern blot and five targeted clones were identified. The integrity of the 5' end in targeted clones was confirmed by PCR amplification from external primers (BR2.8F and BR2.9F, Table 1) to a neo-specific primer (NeoR3.1, Table 1); the product of a targeted allele is ~4.5 kb while no product is expected from the wild type allele (Fig. 1B).

2.2. Cloning and TaqMan RT-PCR analysis of the Δ GB2-Ct gene product

RNA was prepared from whole brain of Δ GB2-Ct mutant mice using the RNeasy Protect Mini Kit (Qiagen Ltd, Crawley, UK) and cDNA was produced using Superscript II reverse transcriptase (Invitrogen Ltd, Paisley, UK), both according to manufacturer's instructions.

The mutated Δ GB2-Ct mRNA was cloned from this cDNA by PCR using gene specific primers and Platinum Taq DNA polymerase (Invitrogen Ltd). PCR was carried out according to manufacturer's instructions (95 °C for 2 min then 30 cycles of 95 °C for 30 s, 58 °C for 30 s, 72 °C for 150 s, then a final extension at 72 °C for 7 min). TaqMan quantitative RT-PCR was carried out as described previously [16]. RNA was prepared from single wild-type, heterozygous and homozygous mouse brains as described above. cDNA synthesis was performed in triplicate on each RNA preparation, and parallel reactions for each mRNA sample were performed in the absence of RT to determine the level of contaminating genomic DNA. TaqMan PCR was performed on the triplicate cDNA samples and the 'no RT' control from each tissue/region studied, using tran-




Fig. 1. C-terminal deletion of the GABA_{B2} receptor subunit. (A) Identification of targeting at the 3' end of GABA_{B2} by Southern blot: genomic DNA from several embryonic stem cell clones was digested with BstX1 and analysed by Southern blot. The probe was derived from the 3' homology arm of the targeting construct. The wild type allele (lanes 1 and 3–8) generates a 5.2 kb band, while the targeted allele (lane 2) gives rise to an additional 5.5 kb band. M: molecular weight marker. Confirmation of the Neo cassette insertion by PCR: PCR amplification of the overlapping region between the 5' homology arm and the Neo cassette was performed using two sets of primer (lanes 1–3 amplified by BR2.8F–NeoR3.1, lanes 4–6 amplified by BR2.9F–NeoR3.1). A 4.5 kb band is obtained from successfully targeted cells (lanes 3 and 6) while no band is expected from wild type samples (lanes 1, 2, 4 and 5). M: molecular weight marker. (C) Amino-acid sequence of the junction between the seventh transmembrane domain (TM7) and the C-terminus of wild-type (WT) and Δ GB2-Ct as deduced from nucleotide sequence analysis of the cloned cDNA. TM7 is boxed and underlined, bordering residue numbers are indicated as well as total number of amino-acids expected in each of the proteins (right-hand side). (D) Real time quantitative RT-PCR analysis of representative wild-type (WT), Δ GB2-Ct homozygous (Δ GB2-Ct) and heterozygous (het) whole-brain total RNA samples using primers and probes specific of the 5' homology arm (5'primers), the targeted exons 14/15 (Δ primers) or the 3' homology arm (3' primers) of GABA_{B2} as indicated on the right-hand side pictogram (E).

script-specific primers and probes. After subtraction of the 'no RT' control, relative levels of the amplified mRNA of interest were normalized to mRNA expression of the 'house-keeping' gene cyclophilin, TaqMan quantitation of which was performed in parallel, to take account of mRNA quality and quantity. The sequences of the primers and probes used were as follows:

- 'Upstream' 5' primer 5'-GCGAAAACACCCACATGACC-3';
- 'Upstream' probe 5'-TCTGGCTCGGCATTGTCTACGC-3';
- 'Upstream' 3' primer 5'-GAACAACATGAGGAGCCCTT-3';
- 'Inside' 5' primer 5'-CCTGACGCAGCCACTCAGA-3';
- 'Inside' probe 5'-CAGGCGATTCCAGTTCACACAGAACCA-3';
- 'Inside' 3' primer 5'-GTGACTGAGGTGGAGGTCTTCG-3';
- 'Downstream' 5' primer 5'-AAAAATCACCTCGATCAAAACCC-3';
- 'Downstream' probe 5'-AGCTCCAGTGAACACGACCGAGC-3';
- 'Downstream' 3' primer 5'-CGCTGGATGTGCTCTGG-3'.

2.3. Preparation, solubilisation and immunoblotting of rat brain membranes

Brain tissue from wild-type and Δ GB2-Ct mice was homogenized using a glass-teflon homogenizer in 10 volumes (~2 ml) of sucrose buffer (5 mM Tris-HCl, pH 7.4, 0.32 M sucrose, 0.1% phenylmethylsulfonyl fluoride, 10 μ g/ml pepstatin, 10 μ g/ml leupeptin, 10 μ g/ml Antipain). The homogenate was centrifuged for 15 min at 1000 \times g and the supernatant saved. The pellet was homogenized again in the same buffer and centrifuged for 15 min at 1000 \times g. The crude membrane fraction was obtained by centrifugation of the pooled resulting supernatants for 30 min at 17 000 \times g. The membranes were washed twice with 50 mM Tris-HCl, pH 7.4 and resuspended in the same buffer to give a protein concentration of ~4 mg/ml. The membranes were then pelleted again, resuspended in 2 ml of solubilisation buffer (10 mM Tris-HCl, pH 7.4, 2% CHAPS, 150 mM NaCl, 1 mM EDTA, 0.1% Phenylmethylsulfonyl fluoride, 10 μ g/ml pepstatin, 10 μ g/ml leupeptin, 10 μ g/ml Antipain) and incubated on a rotating wheel for 3 h at 4 $^{\circ}$ C. Fifty-microliters of the resulting membranes were loaded on a 8% polyacrylamide gel and analysed by SDS-PAGE and immunoblotting.

The antibodies used for immunoblotting were as follows: Anti-GABA_{B1a} antibody has been described previously [17], mouse monoclonal anti-GABA_{B2(C1)} was purchased from BD Biosciences (cat. # 611744) and rabbit polyclonal anti-GAD67 was purchased from Chemicon (cat. # AB5992). Goat anti-rabbit IgG-HRP (cat. # sc-2301) and goat anti-mouse IgG-HRP (cat. # sc-2302) secondary antibodies were purchased from Santa Cruz Biotechnology.

2.4. Biotinylation assay

2.4.1. Antibodies used

An antibody to GABA_{B1} was raised to the N-terminus of GABA_{B1a} and used in immunoblots at a concentration of 2.5 µg/ml. R2 was detected using an antibody to the carboxy-terminus of GABA_{B2} used at 1/1000 (BD-biosciences). Actin was detected using a rabbit anti-actin antibody at 1/1000 (Sigma).

Cortical neurons were prepared from E15 pups using a method described previously [18]. Cortices were individually triturated and plated on 6 cm plates, with no mixing of neurons from different pups. Tails from pups were removed for genotyping. At 7DIV cells were rinsed twice with ice-cold PBS containing 0.5 mM MgCl₂ and 1 mM CaCl₂. They were then biotinylated for 20 min with 1 mg/ml EZ-Link Sulfo-NHS-SS-biotin (Pierce). Cells were then rinsed prior to blocking of remaining biotin in 0.1% BSA/PBS 2 × 10 min. Cells were rinsed again prior to lysis in 0.5 ml RIPA buffer (0.1% SDS, 1% NP-40, 0.5% DOC, 150 mM NaCl, 50 mM Tris–Cl pH 7.4, and complete protease inhibitor cocktail (Boehringer). Cells were solubilised for 1 h with rotation at 4 °C prior to centrifugation (13 000 rpm, 10 min). Supernatants were incubated with a 100 µl of a 1:1 slurry of Neutravidin beads (Pierce) for 2 h with rotation at 4 °C. Beads were then washed in lysis buffer followed by 2 × 15 min washes in high salt (500 mM) lysis buffer and a further wash in low salt lysis buffer. Samples were boiled for 5 min in gel loading buffer. Proteins were separated using 8% SDS-PAGE.

2.4.2. Western blotting

Gels were electrotransferred followed onto nitrocellulose membranes (Hybond-C). Membranes were blocked in 4% milk for 1 h and then probed overnight with primary antibody, followed by detection with hrp-conjugated secondary and chemoluminescence. For detection of anti-GABA_B R1a antibody a 125I conjugated anti-rabbit secondary was used (Amersham). Membranes were then exposed to phosphorimager (Biorad).

2.5. Mouse brain slice preparation

Mice were cervically dislocated 46 weeks after birth and subsequently decapitated in accordance with UK Home Office guidelines. The brain was removed rapidly and

hippocampal slices prepared by cutting 400 µm thick horizontal sections through the whole brain minus the cerebellum using a vibroslicer (Campden Instruments, Loughborough, UK). The hippocampal or cortico-striatal regions from these sections were dissected free from the surrounding brain regions. For sharp and extracellular recordings, slices were placed on a nylon mesh at the interface of warm artificial cerebrospinal fluid (aCSF) and an oxygen-enriched (95% O₂, 5% CO₂), humidified atmosphere as described previously [19,20]. For patch clamp recordings, a submerged chamber perfused with warm aCSF (30 ± 1 °C, 2 ml min⁻¹) was utilised. The standard aCSF perfusion medium for both recording configurations comprised (mM): NaCl, 124; KCl, 3; NaHCO₃, 26; NaH₂PO₄, 1.25; CaCl₂, 2; MgSO₄, 1; D-glucose, 10; and was bubbled with 95% O₂, 5% CO₂ to maintain a pH of 7.3–7.4.

2.6. Intracellular sharp electrode recordings

Intracellular recordings were obtained from the CA1 pyramidal cell body region of the hippocampus or the dorsal striatum (approximately 1–2 mm from the white matter). Following a post dissection 1 h equilibration period neurons were impaled using 2 M (for striatal medium spiny neurons) or 3 M (for hippocampal CA1 pyramidal neurons) potassium acetate-filled microelectrodes (60–100 MΩ). Cells were identified by their characteristic membrane properties [19,21]. An Axoclamp-2B amplifier (Axon Instruments, Foster City, CA, USA) was used in bridge mode or discontinuous current clamp mode. All impalements were made in control aCSF and once stable recordings had been achieved for at least 10 min, experiments were initiated. During the period of the intracellular impalement, the input resistance and extent of spike frequency adaptation of each neuron were measured routinely using 300–600 ms long negative and positive current steps (±0.1–0.4 nA), respectively.

2.7. Extracellular recordings

Extracellular field potential recordings were made from area CA1 of the hippocampal slices using glass microelectrodes (2–4 MΩ) filled with aCSF.

2.8. Whole-cell patch clamp recordings

To study presynaptic hippocampal GABA_B receptor function, whole-cell patch clamp recordings were performed blind targeting the patch pipette at the CA1 *stratum pyramidale* [22]. Whole-cell currents were recorded using an Axopatch 200B (Axon Instruments). Data were acquired with a total gain of 10 at a sampling frequency of 10 kHz and low-pass filtered at 5 kHz. Patch pipettes (2–4 MΩ) were filled with a solution containing (in mM): CsMeSO₄ 130, HEPES 10, EGTA 0.5, NaCl 8, Mg-ATP 4,

Na-GTP 0.3, QX314-Cl 5 (~280 mOsm, pH adjusted to pH 7.2 with CsOH) or K⁺-MeSO₄ 140, HEPES 5, EGTA 1.1, MgCl₂ 2, Mg-ATP 2, Na-GTP 0.3 (~280 mOsm, adjusted to pH 7.2 with K-OH) for some of the paired-pulse depression (PPD) recordings. After reaching whole-cell configuration, the series resistance (R_s) was measured and judged acceptable if below 20 M Ω . R_s was not compensated for. Experiments were discarded if the value of R_s changed by more than 20% or if the holding current spontaneously changed by >200 pA.

2.9. Electrical stimulation

Electrical stimulation was provided by Pt/Ir concentric bipolar electrodes (Frederick Haer & Co, ME, USA). These were positioned in stratum radiatum to stimulate the synaptic inputs to CA1 pyramidal cells or on the white matter–striatal border to stimulate cortical projections to the striatum. In every series of experiments stimuli comprised square-wave pulses (20–200 μ s; 5–30 V) delivered at a fixed intensity every 10–20 s and baseline recordings were made for a minimum of 20 min to ensure stationarity of responses before experiments were initiated.

2.10. Data storage and analysis

Data were captured using pClamp9 software (Axon Instruments Ltd.) or the LTP program shareware [23] (<http://www.ltp-program.com/>). Digitised records were stored on the hard disk of a PC for off-line analysis using Clampfit or LTP software. Data are presented as mean \pm standard error of the mean and, unless otherwise stated, statistical significance was assessed using paired or unpaired Student's *t*-tests performed on raw data with $P < 0.05$ being taken as indicating statistical significance and shown by an asterisk in the Figures. *n* values refer to the number of times a particular experiment was performed, each in a different slice prepared from a different mouse except for the measurement of paired-pulse depression. PPD was calculated using the following equation: $PPD = ((\text{Average IPSC1} - \text{Average IPSC2}) / \text{Average IPSC1}) \times 100$ so as to avoid spurious PP facilitation [24]. Artefact blanking (1 ms) was performed using the LTP program.

2.11. Drugs

Drugs were applied to slices by addition to the perfusion medium. Bicuculline methiodide and 2-chloroadenosine (CADO) were purchased from Sigma (St. Louis, MO). Picrotoxin, [1-(*S*)-3,4-dichlorophenylethyl] amino-2-(*S*)-hydroxypropyl-*p*-benzyl-phosphonic acid (CGP55845A), 2,2-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[*f*]quinoxaline-7-sulphonamide (NBQX), D-2-amino-5-phosphonopentanoate (D-AP5), baclofen, and [D-Ala², NMe-Phe⁴, Gly⁵]-enkephalin (DAMGO) were obtained from Tocris-

Cookson Ltd. (Bristol, UK). QX314 was purchased from Alomone Labs Ltd. (Jerusalem, Israel).

3. Results

3.1. Generation of mice expressing a C-terminally truncated form of GABA_{B2} (Δ GB2-Ct)

Homologous recombination in embryonic stem cells was used to generate a mouse with a C-terminal deletion in the GABA_{B2} subunit (see Section 2 and Fig. 1). In these successfully targeted clones, exons 14 and 15 of GABA_{B2} were replaced with a PGK-neo cassette, which we predicted would result in termination of translation of GABA_{B2} at the end of the seventh transmembrane domain (TM7). Surprisingly, we discovered that the PGK-neo cassette was in fact spliced out in the Δ GB2-Ct mRNA, resulting in a fusion of exons 13 and 16. This caused the addition of six amino acids downstream of TM7 and then a stop codon, as confirmed by cloning and sequencing the cDNA for Δ GB2-Ct from the mutant mice (Fig. 1C). The expression of the mutant mRNA was further confirmed by TaqMan real-time quantitative RT-PCR. This demonstrated, using primer/probe sets both upstream and downstream of the targeted deletion, that the mutant mRNA was both expressed and stable, and using a primer/probe set within the deletion, that no endogenous message for GABA_{B2} was expressed in the Δ GB2-Ct mutant mice (Fig. 1D). In addition, no signal could be detected by immunoblot analysis of Δ GB2-Ct brain tissue using a monoclonal antibody directed against the C-terminus of the GABA_{B2} protein (Fig. 2A). Unfortunately, all commercially available antibodies directed against the N-terminal of GABA_{B2}, in addition to those made in ours and other laboratories, do not recognise the native GABA_{B2} protein by immunohistochemistry or immunoblotting, making direct detection of the truncated protein impossible. However, we were readily able to detect an epitope-tagged version of the truncated GABA_{B2} at the cell surface in transient co-transfection experiments (data not shown). Interestingly, truncation of the GABA_{B2} protein did not influence the level of expression of GABA_{B1} in Δ GB2-Ct mice, as immunoblotting with an anti-GABA_{B1a} antibody (Fig. 2A) did not reveal any overt changes in the expression of GABA_{B1} between wild-type and Δ GB2-Ct brain samples.

3.2. Effect of GABA_{B2(Ct)} deletion on GABA_{B1} subunit trafficking

It has been shown previously that in the absence of GABA_{B2}, the GABA_{B1} receptor subunit is not transported to the cell surface and is retained within intracellular compartments [9,25]. We, therefore, used a cell surface protein biotinylation technique [26] to assess the localisation of the GABA_{B1} protein in Δ GB2-Ct cells, using




Fig. 2. GABA_{B1} and GABA_{B2} protein expression in Δ GB2-Ct mice. (A) Western blots analysis of 50 μ g of brain membranes prepared from WT and Δ GB2-Ct mice using antibodies specific to either GABA_{B1a} (top) or GABA_{B2(Ct)} (middle). Anti-GAD67 (bottom) was used to ensure that equal quantities of proteins were loaded in the two lanes of the GABA_{B1} blot. A similar result with GAD67 was observed for the GABA_{B2} blot. (B) Western blot from lysates of cortical neurons cultured from WT and mutant mice at 7DIV for GABA_{B1a} (top) and actin (bottom). (C) Immunoblot of streptavidin-purified biotinylated surface proteins with an antibody directed against GABA_{B1a}. An antibody to actin was used as a negative control (bottom).

cultured neurons from the cortices of wild-type or mutant mice. In agreement with our data for brain tissue (Fig. 2A), similar levels of GABA_{B1} were present in both wild-type and mutant neurons (Fig. 2B). However, after biotinylation of neuronal cell surface proteins and purification on immobilised streptavidin, we were unable to detect the presence of any GABA_{B1} at the plasma membrane of Δ GB2-Ct neurons (Fig. 2C). Cell surface specificity of the assay was confirmed by the fact that the intracellular protein actin was undetectable.

3.3. Phenotype of the Δ GB2-Ct mutant

The mutation of GABA_{B2} had no effect on the embryonic and early postnatal viability of the Δ GB2-Ct animals, as demonstrated by a Mendelian ratio of wild-type:heterozygous:homozygous genotypes within litters of 10-day-

old animals (21:36:25 among a cohort of 88 animals). In addition, no behavioural effects were observed in heterozygous Δ GB2-Ct mutant mice of any age. However, Δ GB2-Ct homozygous animals exhibited a phenotype that included a lower body weight and reduced life span compared to wild-type littermates, with death occurring in homozygous mutant animals from around 2 weeks of age. Moreover, Δ GB2-Ct mice displayed a conspicuous epileptic phenotype with partial followed by full tonic-clonic signs suggesting secondary generalised seizures. Ictal episodes sometimes provoked sudden death, which explains the postnatal lethality of the phenotype. Accordingly, we found that the pattern of bicuculline-induced epileptiform activity in the CA3 region of hippocampal slices from Δ GB2-Ct mice showed striking differences when compared to the same activity in age-matched wild-type littermates (Fig. 3). The duration ($d_{WT} = 620 \pm$




Fig. 3. Ictal activity in Δ GB2-Ct hippocampal slices. Extracellular recordings in CA3 stratum pyramidale show that exposure to bicuculline 10 μ M causes the appearance of spontaneous epileptiform discharges. As exemplified in the upper panel, bursts were longer and less frequent in the Δ GB2-Ct slices than in the WT ($n = 4$ for both groups, $P < 0.05$ and 0.01 for interval and duration, respectively). Scale bar: 2 mV/50 s or 500 ms.

47 ms; $d_{\Delta\text{GB2-Ct}} = 2972 \pm 430$ ms) as well as the interval between paroxysmal bursts ($i_{\text{WT}} 26.3 \pm 5.4$ s; $i_{\Delta\text{GB2-Ct}} 79.4 \pm 17.0$ s) were significantly longer in the mutants, reflecting the enhanced hyperexcitability of the neuronal network. Cognitive, sensory or motor behavioural analysis was not carried out as the impairment of normal behaviour would have significantly interfered with our interpretation of the results. Nevertheless, the epileptic phenotype is reminiscent of that seen in GABA_{B1} KO mice [27], thus suggesting a similar deficit in GABA_{B} receptor function in the $\Delta\text{GB2-Ct}$ mutant mice.

3.4. Assessment of postsynaptic receptors function

In order to assess GABA_{B} receptor function we performed electrophysiological recordings in hippocampal slices, as the physiological role of the different functional populations of this receptor has been widely characterised in this region of the brain. Single shock stimulation in stratum radiatum of area CA1 in the presence of glutamate receptor antagonists (10 μM NBQX and 50 μM D-AP5) produced a biphasic inhibitory postsynaptic potential (IPSP) in wild-type CA1 pyramidal neurons (Fig. 4A, $n = 7$). This IPSP was composed of a fast (IPSP_A) and a slow component (IPSP_B) that could be blocked by the selective GABA_{A} receptor and GABA_{B} receptor antagonists bicuculline (10 μM) and CGP55845 (1 μM), respectively (data not shown). However, in $\Delta\text{GB2-Ct}$ neurons, whilst the IPSP_A remained intact, the IPSP_B was never observed (Fig. 3A, $n = 15$). Furthermore, in $\Delta\text{GB2-Ct}$ neurons, application of the GABA_{B} receptor agonist baclofen (50 μM) produced no significant change in resting membrane potential whereas in wild-type neurons it caused a robust hyperpolarisation (10–15 mV) that was abolished by 1 μM CGP55845 (Fig. 4B, $n = 3$ for wild-type and mutants). Similarly in whole-cell voltage clamp experiments there was no detectable changes in the holding current of $\Delta\text{GB2-Ct}$ pyramidal cells during application of 50 μM baclofen (data not shown).

3.5. Assessment of presynaptic autoreceptors function

In the hippocampus, as well as in other brain structures, GABA exerts a negative feedback on its own release. A simple method for observing this phenomenon is to record GABA_{A} -mediated inhibitory postsynaptic events in response to two stimuli delivered in quick succession (e.g. 200 ms). This paradigm induces a depression of the second IPSC_A that is mediated, at least in part, by activation of GABA_{B} autoreceptors on inhibitory terminals [19,28,29]. Whereas in wild-type slices this stimulation protocol produced a robust and consistent paired-pulse depression of IPSC_A ($36.4 \pm 3.1\%$, $n = 10$) the average PPD in $\Delta\text{GB2-Ct}$ slices was significantly smaller ($20.0 \pm 0.2\%$, $n = 18$; Fig. 5A). Furthermore, whereas in wild-type slices baclofen (10 μM) caused an average $64.6 \pm 18.4\%$




Fig. 4. Loss of postsynaptic GABA_{B} receptor function in $\Delta\text{GB2-Ct}$ neurons. (A) These traces are sharp electrode intracellular current clamp recordings from putative CA1 pyramidal neurons from a WT (top, $n = 6$) and $\Delta\text{GB2-Ct}$ (bottom, $n = 14$) slice, showing monosynaptic IPSPs in response to a single shock delivered in stratum radiatum, in the presence of 10 μM NBQX and 50 μM D-AP5. These traces are the average of four to eight consecutive traces. Scale bar: 2 mV, 100 ms. (B) This graph shows the effect of bath application of 50 μM baclofen on the resting membrane potential of WT and $\Delta\text{GB2-Ct}$ CA1 pyramidal neurons. In the presence of baclofen, WT neurons show a robust hyperpolarisation, which is reversed by the addition of 1 μM CGP55845 to the perfusing medium ($n = 3$). This hyperpolarisation was never observed in the $\Delta\text{GB2-Ct}$ neurons ($n = 3$). Each point represents mean \pm S.E.M. of the average of four consecutive measurements made every 20 s.

depression of IPSC_A ($n = 3$) it failed to depress the fast inhibitory currents in $\Delta\text{GB2-Ct}$ slices ($-0.3 \pm 2.4\%$; $n = 6$, Fig. 5B). As a control experiment we found that the μ opioid receptor agonist DAMGO depressed IPSC_{AS} in $\Delta\text{GB2-Ct}$ slices (data not shown) [29].

3.6. Assessment of presynaptic heteroreceptors function

Activation of presynaptic GABA_{B} heteroreceptors causes a reduction in the amount of glutamate released from presynaptic terminals and consequently a reduction in EPSC amplitude. In order to examine the presence of these receptors, the magnitude of heterosynaptic depression of EPSCs was examined in wild-type and $\Delta\text{GB2-Ct}$ slices. Specifically, a train of stimuli (five shocks at 50 Hz) was delivered to one set of afferents innervating CA1 pyramidal neurons in wild-type slices which was sufficient to cause spillover of GABA from inhibitory interneurons to activate GABA_{B} heteroreceptors on a separate population of afferents (see illustration in top of Fig. 6A). As previously




Fig. 5. Loss of presynaptic autoreceptor function in Δ GB2-Ct neurons. (A) The traces are monosynaptic IPSCs recorded from WT and Δ GB2-Ct CA1 pyramidal neurons held at -40 mV. These IPSCs are evoked by stimulation in stratum radiatum in the presence of $5 \mu\text{M}$ NBQX and $50 \mu\text{M}$ D-AP5. Two shocks delivered at an interval of 200 ms caused a robust depression of the second IPSC in WT neurons ($n = 10$ from 5 animals). The amount of paired pulse depression was significantly smaller in the mutant slices ($P < 0.00001$, $n = 18$ from 13 animals). Scale bar: 50 pA, 50 ms. (B) Bath-applied baclofen ($10 \mu\text{M}$) induced a depression of the monosynaptic IPSC_A in CA1 pyramidal cells in the WT slice ($64.6 \pm 4.7\%$, $n = 3$). The effect of baclofen is totally absent in Δ GB2-Ct neurons (-0.3 ± 2.4 , $n = 5$). The difference between the effects of baclofen in WT and mutant slices was significant ($P < 0.001$). Baclofen was applied for at least 10 min before measuring the amplitude of evoked IPSCs (peak effect). The traces are the average of 10 – 20 consecutive traces. Scale bar: 25 pA, 50 ms.




Fig. 6. Loss of presynaptic heteroreceptor function in Δ GB2-Ct neurons. (A) Glutamatergic EPSCs were evoked in CA1 pyramidal cells by stimulation of the Schaffer collateral commissural pathway (whole cell voltage clamp configuration, holding potential -70 mV). Two stimulating electrodes were placed in the stratum radiatum and arranged spatially so as to stimulate two independent sets of synapses (cf. schematic in top left hand corner). Two different stimulation epochs were used to reveal the activation of presynaptic GABA_B receptors on glutamatergic terminals (cf. diagram top right hand corner). The first stimulation epoch consisted of a single shock on pathway 1 (naïve EPSC epoch), followed 10 s after by the same shock on pathway 1 but this time preceded 200 ms before by five shocks at 50 Hz on pathway 2 (conditioned EPSC epoch). Traces in the middle panel are superimposed naïve and conditioned EPSCs in response to stimulation on pathway 1 (averages of 10 – 15 traces). In the WT slice the conditioned response (C) was significantly smaller than the naïve response (N) ($P < 0.01$, $n = 4$). This effect was abolished by $1 \mu\text{M}$ CGP55845 ($P < 0.05$). Conditioning did not produce any depression of the EPSC in the Δ GB2-Ct slices ($n = 6$) and CGP55845 had no effect on the N/C ratio. These recordings were carried out in the presence of $50 \mu\text{M}$ picrotoxin and $50 \mu\text{M}$ D-AP5. Traces are average of 15 consecutive traces. Scale bar: 50 pA, 25 ms. (B) Extracellular fEPSPs recorded from stratum radiatum of area CA1 in response to single shock stimulation in the same subfield (top panel). Bath application of $50 \mu\text{M}$ baclofen to the WT slices caused a robust and significant depression ($85 \pm 2\%$ depression) of the slope of the fEPSP that was reversed by addition of $1 \mu\text{M}$ CGP55845. In contrast in the Δ GB2-Ct slices no change in the magnitude of the fEPSP was observed in response to the same concentration of baclofen. The graph in the bottom panel shows the time course of the effects of baclofen and CGP55845 on the fEPSP slope in WT (filled circles, $n = 4$) and Δ GB2-Ct slices (open circles, $n = 4$). Each point represents mean \pm S.E.M. of the average of four consecutive measurements made every 20 s. Scale bars: 1 mV, 10 ms.




Fig. 7. Functional GABA_B receptors are absent in the striatum of Δ GB2-Ct mice. Intracellular sharp electrode recordings from medium spiny neurons of the striatum as identified by their characteristic membrane properties (see [21]). Mixed corticostriatal glutamatergic EPSPs and reversed GABAergic IPSPs were evoked by bipolar stimulation of the white matter between the striatum and cortex. In WT mice bath application of 10 μ M baclofen depressed the corticostriatal synaptic response ($n = 7$). The depression was reversed by 1 μ M CGP55845. The mean percentage change in amplitude (\pm S.E.M.) of the mixed PSP are plotted against time on the left panel. (B) In Δ GB2-Ct mice baclofen (closed bar) failed to depress the corticostriatal synaptic response, indicating a lack of functional GABA_B receptors on the glutamatergic/GABAergic presynaptic terminals. The cholinergic agonist, carbachol (20 mM, CCh, open bar), successfully depressed the synaptic response indicating that presynaptic mechanisms are intact ($n = 6$). Representative synaptic traces, averaged from four consecutive responses, are shown to the right of each graph. Scale bars: 10 mV, 20 ms.

reported by Isaacson et al. [30], this caused a depression of the EPSC evoked by single shock stimulation of these fibres 200 ms after the train; an effect abolished by CGP55845 [31]. In contrast, in every Δ GB2-Ct slice tested no GABA_B receptor-dependent heterosynaptic depression was observed (Fig. 6A). Furthermore, bath application of baclofen (50 μ M) to Δ GB2-Ct slices produced no change in amplitude of extracellularly recorded fEPSPs ($n = 4$) whereas in wild-type slices it caused a large (>80%) depression that was reversed by CGP55845 (Fig. 6B, $n = 3$). In both populations of slices the adenosine A1 receptor agonist 2-chloroadenosine (50 μ M) produced a significant and reversible depression of the fEPSP (data not shown).

3.7. GABA_B receptor function in the striatum

The GABA_{B2} subunit is highly expressed in the hippocampus [17,32,33], whereas in the striatum much lower levels of expression have been reported [4,7,32,34,35]. Because of these low levels of expression in this region, the function of the GABA_B receptor might not depend on GABA_{B2}. To determine whether GABA_B receptors were active in the striatum we examined the effect of baclofen on mixed GABAergic glutamatergic synaptic potentials in medium spiny neurons of the striatum [21]. In wild-type slices corticostriatal postsynaptic potentials evoked by stimulation of the white matter between the striatum and cortex were depressed by bath application of 10 (M baclo-

fen ($n = 7$), an effect that was reversed by 1 μ M CGP55845 (Fig. 7A). No significant effect of either of these drugs on resting membrane potential and input resistance was observed in these experiments. In contrast, in Δ GB2-Ct slices baclofen produced no change in these synaptic potentials although the cholinergic receptor agonist, carbachol (20 μ M) depressed the synaptic response to a similar level to that observed in wild-type slices (Fig. 7B, $n = 6$).

4. Discussion

We have generated a functional knockout of the GABA_{B2} protein in transgenic mice by the deletion of the intracellular C terminal of the receptor subunit, termed Δ GB2-Ct. Using various electrophysiological approaches we show that responses to both endogenous GABA and exogenous GABA_B receptor agonists are absent in tissues obtained from Δ GB2-Ct animals. The loss of GABA_B receptor function was irrespective of the receptor population studied, such that both postsynaptic and presynaptic GABA_B functions were undetectable in the hippocampus of these animals. This loss of function was accompanied by an epileptic phenotype and enhanced epileptiform activity in hippocampal slices, both reminiscent of that observed in animals lacking the GABA_{B1} gene [27]. In the absence of functional GABA_B autoreceptors, PPD was not abolished, demonstrating the existence of several mechanisms con-

tributing to this short-term depression of hippocampal inhibitory transmission as shown previously with GABA_B receptor antagonists [29,36,37]. Regarding excitatory synapses, our study confirms that heterosynaptic depression is entirely and exclusively mediated by activation of GABA_B heteroreceptors [30,31]. The absence of GABA_B receptor function in the striatum is a clear demonstration that even though the GABA_{B2} subunit has been reported to be expressed at low levels in this region [4,7,32,34,35], it is critical for the integrity of classical GABA_B receptor function in this part of the brain.

Although work in heterologous systems has defined roles for GABA_{B2} in the heterodimer, i.e. the coupling of the receptor to the G protein as well as the trafficking of the nascent receptor [9,12,13,38], the exact contribution of this subunit to the formation of native GABA_B receptors is still unknown. In particular, it is still unclear as to whether other proteins expressed in neurons could also play a role in the establishment of GABA_B receptor function. For example we have recently described a third homologous putative GPCR subunit, GABA_{BL}, that is expressed in the mammalian CNS, although it appears unable to participate in the expression of a functional GABA_B receptor in heterologous systems [39]. Similarly it has been suggested that GABA_{B1} can be trafficked to the cell surface by mGluR4 [40]. The present work however suggests that, in the neurons we studied, there were no proteins that could promote GABA_{B1} surface expression and therefore that GABA_{B2} is probably the only protein that mediates this function. Indeed, we provide evidence that the loss of GABA_B receptor function is due to the alteration of the correct trafficking of GABA_{B1}, by showing that the GABA_{B1} subunit was absent from the surface of Δ GB2-Ct cortical neurons in culture. Previous work in heterologous systems has established a role for the GABA_{B2} tail in masking the ER-retention signal present in the C-terminus of GABA_{B1} [8,9,11]. Our work demonstrates that the GABA_{B2} subunit is crucial for the trafficking of GABA_{B1} to the cell surface of neurons in a native environment. Therefore, if the GABA_{B1} subunit is absent, as is the case in GABA_{B1} knockout mice, or not addressed to the cell surface, as in this study, then there is no resultant GABA_B receptor function.

Although the presence of the truncated GABA_{B2} protein could not be confirmed directly, several lines of evidence indicate that it is stably expressed in Δ GB2-Ct mice. The levels of GABA_{B1} protein expression were similar in wild-type and mutant animals, an observation that is in sharp contrast to the GABA_{B1} knockout mouse where GABA_{B2} protein expression was decreased [27,41]. More importantly, it is strikingly different from the dramatic down-regulation of the GABA_{B1} protein observed in mice in which the GABA_{B2} gene has been deleted [47]. This suggests that GABA_B subunit interactions promote protein stability and that if one of the subunits is missing the other tends to be degraded. We

have previously shown that deletion of the C-terminal domain of GABA_{B2} does not prevent its heterodimerisation with GABA_{B1} [9], suggesting that stable GABA_B heteromer formation occurs intracellularly in Δ GB2-Ct mice and prevents the degradation of GABA_{B1}. In addition, in the complete absence of GABA_{B2}, it has been demonstrated that baclofen induces a small inward current specifically mediated by GABA_B receptors [47]. This effect is not observed in Δ GB2-Ct mice, consistent with stable expression of a truncated version of GABA_{B2}, as if the truncated GABA_{B2} protein were degraded it is likely that we would observe a similar baclofen-induced inward current. This raises the possibility that GABA_{B1} is able to function, either on its own or in association with other unidentified proteins, as a non-canonical GABA_B receptor in cells where GABA_{B2} is not expressed. It is important to emphasise that the transgenic approach we have employed in this study would not reveal such a GABA_{B1}-mediated function, due to the complete absence of GABA_{B1} at the plasma membrane. Therefore, the two studies are not contradictory, and moreover it does not alter the general conclusion from both genetic approaches; that GABA_{B2} is an absolute requirement for the formation of receptors mediating 'classical' GABA_B function in the brain. In addition it has previously been shown that the C-terminus of GABA_{B2} is neither required for the coupling of GABA_B receptors to G-proteins [10,12–15] nor for the correct expression of this subunit at the cell surface [9]. Assuming that the same truncated GABA_{B2} protein is indeed expressed in Δ GB2-Ct mice, these results strongly suggest that GABA_{B1} is the only GABA-binding protein able to form a functional GABA_B receptor in association with GABA_{B2}.

In this study, we observed a loss of GABA_B receptor function in several areas of the brain, such as hippocampus, striatum and neocortex, suggesting that the presence of the GABA_{B2} protein may be crucial for the formation of functional GABA_B receptors throughout the brain. It has been suggested previously that GABA_B receptors in the CNS are exclusively heterodimers [42]. Furthermore, we propose that the GABA_{B1/2} heterodimer is the only form of receptor mediating classical GABA_B receptor function in the central nervous system. This contrasts with other neurotransmitter systems where slow synaptic transmission is mediated by several G protein-coupled receptors that coexist either as mono- or oligomers [43–46]. To our knowledge, the GABA_B receptor heterodimer is the only neurotransmitter-activated GPCR that exhibits the property of being a unique metabotropic receptor for a defined transmitter, i.e. GABA. Consistent with this hypothesis no additional genes to those encoding GABA_{B1} [7] and GABA_{B2} [2–4] have been identified that code for a functional GABA_B receptor subunit. The discovery of a putative "GABA_{B3}" gene seems unlikely unless its product mediates functions that are not as yet associated with the GABA_B receptor.

References

- [1] Calver AR, Davies CH, Pangalos MN. GABA_B receptors: from monogamy to promiscuity. *Neurosignals* 2002;11:299–314.
- [2] Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. *Nature* 1998;396:683–7.
- [3] White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, et al. Heterodimerization is required for the formation of a functional GABA(B) receptor. *Nature* 1998;396:679–82.
- [4] Kuner R, Kohr G, Grunewald S, Eisenhardt G, Bach A, Kornau HC. Role of heteromer formation in GABA(B) receptor function. *Science* 1999;283:74–7.
- [5] Marshall FH, Jones KA, Kaupmann K, Bettler B. GABA(B) receptors—the first 7TM heterodimers. *Trends Pharmacol Sci* 1999;20:396–9.
- [6] Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. *Trends Pharmacol Sci* 2001;22:532–7.
- [7] Kaupmann K, Hugel K, Heid J, Flor PJ, Bischoff S, Mickel SJ, et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. *Nature* 1997;386:239–46.
- [8] Margeta-Mitrovic M, Jan YN, Jan LY. A trafficking checkpoint controls GABA(B) receptor heterodimerization. *Neuron* 2000;27:97–106.
- [9] Calver AR, Robbins MJ, Cosio C, Rice SQ, Babbs AJ, Hirst WD, et al. The C-terminal domains of the GABA(b) receptor subunits mediate intracellular trafficking but are not required for receptor signaling. *J Neurosci* 2001;21:1203–10.
- [10] Galvez T, Duthey B, Kniazeff J, Blahos J, Rovelli G, Bettler B, et al. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. *EMBO J* 2001;20:2152–9.
- [11] Pagano A, Rovelli G, Mosbacher J, Lohmann T, Duthey B, Stauffer D, et al. C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(b) receptors. *J Neurosci* 2001;21:1189–202.
- [12] Margeta-Mitrovic M, Jan YN, Jan LY. Function of GB1 and GB2 subunits in G protein coupling of GABA(B) receptors. *Proc Natl Acad Sci USA* 2001;98:14649–54.
- [13] Robbins MJ, Calver AR, Filippov AK, Hirst WD, Russell RB, Wood MD, et al. GABA(B2) is essential for g-protein coupling of the GABA(B) receptor heterodimer. *J Neurosci* 2001;21:8043–52.
- [14] Duthey B, Caudron S, Perroy J, Bettler B, Fagni L, Pin JP, et al. A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. *J Biol Chem* 2002;277:3236–41.
- [15] Havlickova M, Prezeau L, Duthey B, Bettler B, Pin JP, Blahos J. The intracellular loops of the GB2 subunit are crucial for G-protein coupling of the heteromeric gamma-aminobutyrate B receptor. *Mol Pharmacol* 2002;62:343–50.
- [16] Medhurst AD, Harrison DC, Read SJ, Campbell CA, Robbins MJ, Pangalos MN. The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models. *J Neurosci Methods* 2000;98:9–20.
- [17] Calver AR, Medhurst AD, Robbins MJ, Charles KJ, Evans ML, Harrison DC, et al. The expression of GABA(B1) and GABA(B2) receptor subunits in the CNS differs from that in peripheral tissues. *Neuroscience* 2000;100:155–70.
- [18] Kittler JT, Delmas P, Jovanovic JN, Brown DA, Smart TG, Moss SJ. Constitutive endocytosis of GABA_A receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. *J Neurosci* 2000;20:7972–7.
- [19] Davies CH, Davies SN, Collingridge GL. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. *J Physiol* 1990;424:513–31.
- [20] Thuaux SJ, Davies CH, Randall AD, Collingridge GL. Group I mGluRs modulate the pattern of non-synaptic epileptiform activity in the hippocampus. *Neuropharmacology* 2002;43:141–6.
- [21] Spencer JP, Murphy KP. Bi-directional changes in synaptic plasticity induced at corticostriatal synapses in vitro. *Exp Brain Res* 2000;135:497–503.
- [22] Blanton MG, Lo Turco JJ, Kriegstein AR. Whole cell recording from neurons in slices of reptilian and mammalian cerebral cortex. *J Neurosci Methods* 1989;30:203–10.
- [23] Anderson WW, Collingridge GL. The LTP program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. *J Neurosci Methods* 2001;108:71–83.
- [24] Kim J, Alger BE. Random response fluctuations lead to spurious paired-pulse facilitation. *J Neurosci* 2001;21:9608–18.
- [25] Couve A, Filippov AK, Connolly CN, Bettler B, Brown DA, Moss SJ. Intracellular retention of recombinant GABA_B receptors. *J Biol Chem* 1998;273:26361–7.
- [26] Fairfax BP, Pitcher JA, Scott MG, Calver AR, Pangalos MN, Moss SJ, et al. Phosphorylation and chronic agonist treatment atypically modulate GABA_B receptor cell surface stability. *J Biol Chem* 2004;279:12565–73.
- [27] Prosser HM, Gill CH, Hirst WD, Grau E, Robbins M, Calver A, et al. Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice. *Mol Cell Neurosci* 2001;17:1059–70.
- [28] Davies CH, Collingridge GL. The physiological regulation of synaptic inhibition by GABA_B autoreceptors in rat hippocampus. *J Physiol* 1993;472:245–65.
- [29] Lambert NA, Wilson WA. Heterogeneity in presynaptic regulation of GABA release from hippocampal inhibitory neurons. *Neuron* 1993;11:1057–67.
- [30] Isaacson JS, Solis JM, Nicoll RA. Local and diffuse synaptic actions of GABA in the hippocampus. *Neuron* 1993;10:165–75.
- [31] Davies CH, Pozza MF, Collingridge GL. CGP 55845A: a potent antagonist of GABA_B receptors in the CA1 region of rat hippocampus. *Neuropharmacology* 1993;32:1071–3.
- [32] Bischoff S, Leonhard S, Reymann N, Schuler V, Shigemoto R, Kaupmann K, et al. Spatial distribution of GABA(B)R1 receptor mRNA and binding sites in the rat brain. *J Comp Neurol* 1999;412:1–16.
- [33] Margeta-Mitrovic M, Mitrovic I, Riley RC, Jan LY, Basbaum AI. Immunohistochemical localization of GABA(B) receptors in the rat central nervous system. *J Comp Neurol* 1999;405:299–321.
- [34] Martin SC, Russek SJ, Farb DH. Molecular identification of the human GABABR2: cell surface expression and coupling to adenylyl cyclase in the absence of GABABR1. *Mol Cell Neurosci* 1999;13:180–91.
- [35] Clark JA, Mezey E, Lam AS, Bonner TI. Distribution of the GABA(B) receptor subunit gb2 in rat CNS. *Brain Res* 2000;860:41–52.
- [36] Lambert NA, Wilson WA. Temporally distinct mechanisms of use-dependent depression at inhibitory synapses in the rat hippocampus in vitro. *J Neurophysiol* 1994;72:121–30.
- [37] Caillard O, McLean HA, Ben-Ari Y, Gaiarsa JL. Ontogenesis of presynaptic GABA_B receptor-mediated inhibition in the CA3 region of the rat hippocampus. *J Neurophysiol* 1998;79:1341–8.
- [38] Margeta-Mitrovic M, Jan YN, Jan LY. Ligand-induced signal transduction within heterodimeric GABA(B) receptor. *Proc Natl Acad Sci USA* 2001;98:14643–8.
- [39] Calver AR, Michalovich D, Testa TT, Robbins MJ, Jaillard C, Hill J, et al. Molecular cloning and characterisation of a novel GABAB-related G-protein coupled receptor. *Brain Res Mol Brain Res* 2003;110:305–17.
- [40] Sullivan R, Chateaufneuf A, Coulombe N, Kolakowski Jr LF, Johnson MP, Hebert TE, et al. Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors with truncated receptors and metabotropic glutamate receptor 4 supports the GABA(B) heterodimer as the functional receptor. *J Pharmacol Exp Ther* 2000;293:460–7.
- [41] Schuler V, Luscher C, Blanchet C, Klix N, Sansig G, Klebs K, et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre- and post-synaptic GABA(B) responses in mice lacking GABA(B1). *Neuron* 2001;31:47–58.

- [42] Benke D, Honer M, Michel C, Bettler B, Mohler H. Gamma-amino-butyric acid type B receptor splice variant proteins GBR1a and GBR1b are both associated with GBR2 in situ and display differential regional and subcellular distribution. *J Biol Chem* 1999;274:27323–30.
- [43] Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. *Neuropharmacology* 1995;34:1–26.
- [44] Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. *Annu Rev Pharmacol Toxicol* 1997;37:205–37.
- [45] Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. *EMBO J* 1999;18:1723–9.
- [46] Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. *Annu Rev Pharmacol Toxicol* 2002;42:409–35.
- [47] Gassmann M, Shaban H, Vigot R, Sansig G, Haller C, Barbieri S, et al. Redistribution of GABA_{B(1)} protein and atypical GABA_B responses in GABA_{B(2)}-deficient mice. *J Neurosci* 2004;24:6086–97.